Chanos, Simons Among the Billionaires Betting on This Infrastructure Giant

RENAISSANCE TECHNOLOGIESIn July, Chicago Bridge and Iron Company N.V. (NYSE:CBI) announced plans to acquire Shaw Group Inc. (NYSE:SHAW) at $46 per share. Chicago saw an over 15% drop in its shares on the Shaw acquisition news. On the other hand, shares of Shaw were up over 50%. The acquisition price for Shaw is $46, while the company is currently trading at less than $44 a share.

At the end of 2Q, both companies had serious billionaire fund managers as shareholders—including the likes of D.E. Shaw, Steven Cohen, Jim Chanos and Jim Simons. We believe these managers were bullish on what these companies could do separately, but are aggressively bullish on what they can accomplish together. The Shaw acquisition will give Chicago more of a presence in the energy sector, while favorable petrochemical prospects will continue to drive its core business.

Shaw has plans to ramp up its nuclear projects in 2013. The company has seen margins contract on cost overruns on nuclear and coal projects. As well, the company is finalizing the sale of its energy and chemicals unit, while also completing the sale of its 20% stake in Westinghouse—back to Toshiba—which will eliminate all of its $1.7 billion debt.

Prior to the acquisition offer, Shaw was down year to date 15%, having had a couple huge earnings misses. August 2011 earnings miss came in at 176%, posting actual EPS of negative $0.44 versus estimates of $0.58. Then in May 2012, the company missed EPS again, posting negative $0.09 EPS versus estimates of $0.58.

Chicago is expected to see a revenue increase of 23% in 2012, and continued strengthening into 2013. Chicago also boasts a backlog of $28 billion—which is expected to put next year EPS up 18%. Some of the biggest competitors for the potential Shaw-Chicago conglomerate will be KBR, Inc. (NYSE:KBR), Jacobs Engineering Group Inc (NYSE:JEC) and Fluor Corporation (NYSE:FLR).

KBR reported 2Q net income of $104 million or $0.70 per share compared to net income of $100 million or $0.65 per share in the second quarter of 2011. Earnings next year are expected to come in 18% higher. KBR has announced a couple key contracts with the likes of DuPont and Dominion Resources, and is up 7% year to date. The company also upped its earnings guidance for the year 2012, calling for EPS of $2.60 to $2.80, previous estimates were $2.45 to $2.80.

Jacobs, seeing strength in its upstream oil and gas, and chemicals sectors, expects EPS to come in up at an estimated 13% higher next year. Backlogs have rose 11% to $15.6 billion from a year ago. Fluor is the powerhouse of the industry, with a market cap of around $9 billion. Fluor is expected to see a 20% increase in 2012 revenues, with its oil and gas segment being the driving force. The company is also expected to see a positive an increase in revenue mix, with a solid backlog in the chemical segment.

Fluor saw Carlson Capital increase its position by 62% in 2Q, while Jacobs and KBR saw common interest from notable firms Royce & Associates and Platinum Asset Management. Platinum was the top fund owner by shares in Jacobs, while also upping its stake in KBR by 23% over the quarter. The second largest owner of Jacobs by shares was Royce & Associates, who also owned 1.7 million shares of KBR. Worth noting for KBR is the recent insider sale by the company’s CEO.

The top five fund owners were all upping their stakes in Shaw during 2Q, most notably D.E. Shaw and Steven Cohen, by 41% and 318% respectively. For Chicago, Jim Chanos and Jim Simons were modest owners, while Columbus Circle Investors was the top fund owner, with 3.1 million shares invested. Click here to see all funds owning Shaw and all funds owning Chicago. Each of these engineering and construction firms have top fund managers owning a piece of the action, but we believe that a Chicago-Shaw combo could be the most impressive powerhouse of the bunch.

Biotech Insider Alert - $6 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

Most Famous Gay Athletes

The World’s Most Famous Circuses

Best Hair Stylists

Most Popular NASCAR Drivers

The Best Romance Movies of all Time

The Most Wanted Drug Lords

The Oldest Money Managers

The Greatest Directors in the World

Largest Animals in the World

World’s Most Expensive Desserts

Best Selling Comic Books of All Time

A-list Actors who Sabotaged Their Career

Rappers With a College Degree

The Best Jazz Albums of all Time

The Most Influential Jazz Musicians

The World’s Most Famous Photographers

The Best Oscar-Winning Songs

Most Influential Choreographers Ever

Most Expensive Department Stores in the World

The Most Expensive Stolen Paintings in the World

The World’s Most Expensive Teas

Top Oscar Record Holders

The Most Expensive Flowers in the World

Countries With a Booming Film Industry

Most Expensive Cupcakes in the World

Uncommon European Escapes

The Most Stolen Artists in History

Best Travel Destinations in Australia

World’s Most Expensive Musical Instruments

World’s Most Famous Animals

Most Expensive Cakes in the World

Most Expensive Kosher Champagne in the World

Most Expensive Kosher Wine in the World

The Most Surprisingly Dark Fairy Tales

Most Popular Travel Destinations in Asia

The 10 Most Expensive Dresses Ever Worn to the Oscars

World’s Most Visited Art Museums

Best Countries for Photographers to Work in

Best Paid Jobs in the Film Industry

The Most Renowned Recovered Paintings Ever

Child Stars That Turned out Just Fine

Books That Were Banned in the Past Century

World’s Richest Dancers

Best Remedies against Bad Breath

Foods That Improve Your Skin Texture

Best-Selling Children’s Books of all Time

Foods That Boost Your Libido

Best-Selling Books of all Time

The Most Expensive Academy Awards Jewelry in History

Most Expensive Japanese Restaurant In New York City

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!